Publications by authors named "Jennifer M Segar"

Claim this Profile
A
Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors.
Jianhui Ma, Wen Liu, Jiali Li, Daehwan Kim, Sangyub Kim, Jennifer M Segar

Mol Cancer Ther· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MicroRNAs: Emerging as Highly Promising Biomarkers for Early Breast Cancer Screening.
Karl Krupp, Jennifer M Segar, Juan Lewis Fernández-Martínez, Purnima Madhivanan

J Clin Lab Med· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinicopathological and Molecular Characteristics of Pleomorphic Invasive Lobular Carcinoma.
Jennifer M Segar, Ritu Pandey, Kiah J Farr, Raymond Nagle, Lauren LeBeau

Int J Breast Cancer· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II Study of Irinotecan and Etoposide as Treatment for Refractory Metastatic Breast Cancer.
Jennifer M Segar, Darien Reed, Alison Stopeck, Robert B Livingston, Pavani Chalasani

Oncologist· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
Seongseok Yun, Nicole D Vincelette, Jennifer M Segar, Yimin Dong, Yang Shen

Clin Lymphoma Myeloma Leuk· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathophysiology of tumour-induced microangiopathic haemolytic anaemia.
Pavani Chalasani, Jennifer M Segar, Marilyn Marron, Alison Stopeck

BMJ Case Rep· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis